Vertex Pharmaceuticals Inc

Research Vertex Pharmaceuticals Inc (VRTX) on Bullrun: valuation model: 3.7% undervalued, market cap USD 126.81B, P/E 29.6. Explore financials, valuation history, model signals, and stock context.

Key Metrics

• TickerVRTX
• ExchangeNASDAQ
• CountryUnited States
• SectorHealthcare
• IndustryBiotechnology
• CurrencyUSD
• Valuation signal3.7% undervalued
• Market capUSD 126.81B
• P/E29.6
• Financial periodFY2025
• RevenueUSD 12.00B
• Revenue growth8.9%
• Net incomeUSD 3.95B
• Free cash flowUSD 3.19B
• Gross margin86.2%

Valuation Snapshot

Bullrun's latest valuation model marks Vertex Pharmaceuticals Inc as 3.7% undervalued; latest market cap is USD 126.81B; P/E is 29.6.

About Vertex Pharmaceuticals Inc

Vertex Pharmaceuticals Incorporated operates as a biotechnology company in the United States, Europe, and internationally. The company offers transformative medicines for people with serious diseases with a focus on specialty markets, such as cystic fibrosis (CF), sickle cell disease (SCD), transfusion dependent beta thalassemia (TDT), and acute pain. It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age and older;

Frequently asked questions

Is Vertex Pharmaceuticals Inc overvalued or undervalued?

Bullrun's valuation model currently marks Vertex Pharmaceuticals Inc as 3.7% undervalued.

What is Vertex Pharmaceuticals Inc's market cap?

Vertex Pharmaceuticals Inc's market capitalization is USD 126.81B.

What is Vertex Pharmaceuticals Inc's P/E ratio?

Vertex Pharmaceuticals Inc's price-to-earnings (P/E) ratio is 29.6.

What does Vertex Pharmaceuticals Inc do?

Vertex Pharmaceuticals Incorporated operates as a biotechnology company in the United States, Europe, and internationally.